The Federal Reserve maintained a status quo in its policy interest rate on Wednesday, leaving it at the near-zero level it was lowered to in the last policy meet. Even though the central bank acknowledged that the U.S. economy is expected to grow at an increased pace in the near term, it maintained that there was no likelihood of interest rate hikes till 2023.
The Federal Open Market Committee’s (FOMC) optimistic outlook for inflation and GDP growth was accompanied by lowered expectations for the rate of unemployment. The Federal Reserve also announced its intention to continue with its asset purchase program, the monthly purchase of bonds worth at least $120 billion.
The Federal Reserve’s two-day policy meeting this week comes against an interesting backdrop – rising expectations of a speedy recovery of the U.S. economy owing largely to the rollout of the coronavirus vaccine, yields on U.S. 10-year Treasury notes rising rapidly, escalating interest rates and risk of inflation.
The release of the President Biden’s $1.9 trillion economic rescue package only a few days ago, though welcomed by many, has added to elevated government borrowings and a burgeoning fiscal deficit. The U.S. Government has spent $5 trillion on economic stimulus packages till date.
Federal Reserve Chairman Jerome Powell recently gave an indication of his intention to continue with an easy monetary policy, when, at the Senate Banking Committee held in February, he was quoted, “We’re 10 million jobs below where we were in February of 2020. 10 million payroll jobs. So, there’s a long way to go,” he said. “Monetary policy is accommodative, and it needs to continue to be accommodative … right now, we’ve had three months (averaging) 29,000 jobs a month. It’s not very much progress.”
Neurological and neurodegenerative diseases affect a vast segment of the population worldwide and there is a significant demand for treatments for these conditions. Biogen (BIIB) has a strong portfolio of
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA), a market leader in generic drugs, reported lower revenues for the third quarter of 2021, citing a slowdown in North American sales. Meanwhile, earnings
Goldman Sachs (GS) exceeded analysts’ expectations, as investment banking revenue surged nearly 90%. Goldman market research report covers key aspects about the firm including company profile, financial highlights and key